{"title":"CAR-T 细胞疗法:改变癌症治疗及其他领域的游戏规则","authors":"Kumar Utkarsh, Namita Srivastava, Sachin Kumar, Azhar Khan, Gunjan Dagar, Mukesh Kumar, Mayank Singh, Shabirul Haque","doi":"10.1007/s12094-023-03368-2","DOIUrl":null,"url":null,"abstract":"<p>In recent years, cancer has become one of the primary causes of mortality, approximately 10 million deaths worldwide each year. The most advanced, chimeric antigen receptor (CAR) T cell immunotherapy has turned out as a promising treatment for cancer. CAR-T cell therapy involves the genetic modification of T cells obtained from the patient's blood, and infusion back to the patients. CAR-T cell immunotherapy has led to a significant improvement in the remission rates of hematological cancers. CAR-T cell therapy presently limited to hematological cancers, there are ongoing efforts to develop additional CAR constructs such as bispecific CAR, tandem CAR, inhibitory CAR, combined antigens, CRISPR gene-editing, and nanoparticle delivery. With these advancements, CAR-T cell therapy holds promise concerning potential to improve upon traditional cancer treatments such as chemotherapy and radiation while reducing associated toxicities. This review covers recent advances and advantages of CAR-T cell immunotherapy.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"117-119 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CAR-T cell therapy: a game-changer in cancer treatment and beyond\",\"authors\":\"Kumar Utkarsh, Namita Srivastava, Sachin Kumar, Azhar Khan, Gunjan Dagar, Mukesh Kumar, Mayank Singh, Shabirul Haque\",\"doi\":\"10.1007/s12094-023-03368-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In recent years, cancer has become one of the primary causes of mortality, approximately 10 million deaths worldwide each year. The most advanced, chimeric antigen receptor (CAR) T cell immunotherapy has turned out as a promising treatment for cancer. CAR-T cell therapy involves the genetic modification of T cells obtained from the patient's blood, and infusion back to the patients. CAR-T cell immunotherapy has led to a significant improvement in the remission rates of hematological cancers. CAR-T cell therapy presently limited to hematological cancers, there are ongoing efforts to develop additional CAR constructs such as bispecific CAR, tandem CAR, inhibitory CAR, combined antigens, CRISPR gene-editing, and nanoparticle delivery. With these advancements, CAR-T cell therapy holds promise concerning potential to improve upon traditional cancer treatments such as chemotherapy and radiation while reducing associated toxicities. This review covers recent advances and advantages of CAR-T cell immunotherapy.</p>\",\"PeriodicalId\":10166,\"journal\":{\"name\":\"Clinical and Translational Oncology\",\"volume\":\"117-119 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-023-03368-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12094-023-03368-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
近年来,癌症已成为导致死亡的主要原因之一,全球每年约有 1 000 万人死于癌症。最先进的嵌合抗原受体(CAR)T 细胞免疫疗法已成为治疗癌症的有效方法。CAR-T 细胞疗法包括对从患者血液中提取的 T 细胞进行基因改造,然后输回患者体内。CAR-T 细胞免疫疗法大大提高了血液肿瘤的缓解率。目前,CAR-T 细胞疗法仅限于血液癌症,但人们正在努力开发更多的 CAR 构建,如双特异性 CAR、串联 CAR、抑制性 CAR、联合抗原、CRISPR 基因编辑和纳米颗粒递送。随着这些技术的进步,CAR-T 细胞疗法有望改善化疗和放疗等传统癌症治疗方法,同时减少相关毒性。本综述将介绍 CAR-T 细胞免疫疗法的最新进展和优势。
CAR-T cell therapy: a game-changer in cancer treatment and beyond
In recent years, cancer has become one of the primary causes of mortality, approximately 10 million deaths worldwide each year. The most advanced, chimeric antigen receptor (CAR) T cell immunotherapy has turned out as a promising treatment for cancer. CAR-T cell therapy involves the genetic modification of T cells obtained from the patient's blood, and infusion back to the patients. CAR-T cell immunotherapy has led to a significant improvement in the remission rates of hematological cancers. CAR-T cell therapy presently limited to hematological cancers, there are ongoing efforts to develop additional CAR constructs such as bispecific CAR, tandem CAR, inhibitory CAR, combined antigens, CRISPR gene-editing, and nanoparticle delivery. With these advancements, CAR-T cell therapy holds promise concerning potential to improve upon traditional cancer treatments such as chemotherapy and radiation while reducing associated toxicities. This review covers recent advances and advantages of CAR-T cell immunotherapy.